In light of the significant correlation between inflammatory alterations andmetabolic dysfunction throughout different stages of metabolic disease progression, we focused on utilizing our previously characterized glitazone-derived anti inflammatory 1,2,3-triazoles as lead compounds to create new multitargetdirectedligands that interact with COX-2,peroxisome proliferator-activated receptor γ (PPARγ), and CAwithin the framework of metabolic disorders. Notably, seven compounds exhibited equivalent or similar COX-2 inhibitory effects to celecoxib. Four compounds, namely, 3b, 3e, 5e, and 5h, exhibited substantial nanomolar inhibitory effects against hCAI, II, IV, and IX isoforms (Ki 8.5−833, 0.37−24.6, 44.2−777, and 27.3−32.1 nM, respectively). Furthermore, compounds 5e and5hdemon stratedasignificant increase in glucose uptake in the rat hemidiaphragm experiment, outperforming pioglitazone. A robust PPARγ agonisminluciferaseassay, full-lengthhumanPPARγ transactivationwithout artificially increasing itsexpression, andisothermal titration calorimetry for Kd determination were used to substantiate theirPPARγ-dependent insulin-sensitizing activity. In vivo pharmacokinetic and tissue distribution experiments were carried out, revealing favorableproperties.The invitroactivitieswere reflected into effective in vivo anti-inflammatory potential in the formalin-induced rat paw edema assay, and they also exhibited a favorable ulcerogenic profile. Furthermore, computational target prediction and network pharmacology analysis for the two most active molecules,5e and 5h, identified important biological pathways associated with the intended outcomes. In this regard, 5e and 5h not only mitigated hyperglycemia and insulin resistance in an in vivo rat model of type 2 diabetes but also protected against renal and lipemic damage caused by metabolic dysfunction. Finally, docking simulations indicated potential binding interactions with the intended biological targets.
Elzahhar, P.A., Nematalla, H.A., Abouayana, M.A., El Ashry, E.S.H., Balbaa, M., Petreni, A., et al. (2025). Multi-Target Glitazones for Modulating Peroxisome Proliferator-Activated Receptor-γ, Cyclooxygenase-2, and Carbonic Anhydrases for the Management of Metabolic Dysfunction. ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 8(6), 1627-1658 [10.1021/acsptsci.5c00011].
Multi-Target Glitazones for Modulating Peroxisome Proliferator-Activated Receptor-γ, Cyclooxygenase-2, and Carbonic Anhydrases for the Management of Metabolic Dysfunction
Spagnuolo, Rosaria;Naldi, Marina;Bartolini, Manuela;
2025
Abstract
In light of the significant correlation between inflammatory alterations andmetabolic dysfunction throughout different stages of metabolic disease progression, we focused on utilizing our previously characterized glitazone-derived anti inflammatory 1,2,3-triazoles as lead compounds to create new multitargetdirectedligands that interact with COX-2,peroxisome proliferator-activated receptor γ (PPARγ), and CAwithin the framework of metabolic disorders. Notably, seven compounds exhibited equivalent or similar COX-2 inhibitory effects to celecoxib. Four compounds, namely, 3b, 3e, 5e, and 5h, exhibited substantial nanomolar inhibitory effects against hCAI, II, IV, and IX isoforms (Ki 8.5−833, 0.37−24.6, 44.2−777, and 27.3−32.1 nM, respectively). Furthermore, compounds 5e and5hdemon stratedasignificant increase in glucose uptake in the rat hemidiaphragm experiment, outperforming pioglitazone. A robust PPARγ agonisminluciferaseassay, full-lengthhumanPPARγ transactivationwithout artificially increasing itsexpression, andisothermal titration calorimetry for Kd determination were used to substantiate theirPPARγ-dependent insulin-sensitizing activity. In vivo pharmacokinetic and tissue distribution experiments were carried out, revealing favorableproperties.The invitroactivitieswere reflected into effective in vivo anti-inflammatory potential in the formalin-induced rat paw edema assay, and they also exhibited a favorable ulcerogenic profile. Furthermore, computational target prediction and network pharmacology analysis for the two most active molecules,5e and 5h, identified important biological pathways associated with the intended outcomes. In this regard, 5e and 5h not only mitigated hyperglycemia and insulin resistance in an in vivo rat model of type 2 diabetes but also protected against renal and lipemic damage caused by metabolic dysfunction. Finally, docking simulations indicated potential binding interactions with the intended biological targets.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


